ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.110,38
-0,16%
S&P 500
5.667,20
0,64%
US Dollar vs BRL
5,4259
-0,41%
Bitcoin
65.011,07
0,25%
Brent Oil
83,315
-1,22%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Notícias

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH
DataHoraFonteTítuloCódigoCompanhia
04/09/200709:00PR Newswire (US)Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/08/200709:00PR Newswire (US)Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/08/200710:00PR Newswire (US)Allos Therapeutics Reports Second Quarter 2007 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
18/07/200709:00PR Newswire (US)Allos Therapeutics to Report 2007 Second Quarter Financial Results on August 7, 2007NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
25/06/200710:30PR Newswire (US)Allos Therapeutics Selected to Join Russel 3000 IndexNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/06/200707:30PR Newswire (US)Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From BreastNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
31/05/200718:01PR Newswire (US)Allos Therapeutics Initiates Phase I/II Study of PDX and Gemcitabine in Patients With Non-Hodgkin's Lymphoma or Hodgkin's DiseasNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/05/200718:55PR Newswire (US)Allos Therapeutics Files Shelf Registration StatementNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/05/200709:30PR Newswire (US)Allos Therapeutics Reports First Quarter 2007 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/05/200714:21PR Newswire (US)Allos Therapeutics to Announce 2007 First Quarter Results on Tuesday, May 8NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
26/04/200709:00PR Newswire (US)Allos Therapeutics Appoints Dr. Jeffrey R. Latts to Its Board of DirectorsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/04/200709:30PR Newswire (US)Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European CommissionNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/03/200709:00PR Newswire (US)Allos Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Medical OfficerNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/03/200709:00PR Newswire (US)Allos Therapeutics Reports Fourth Quarter and 2006 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
27/02/200710:00PR Newswire (US)Allos Therapeutics to Report 2006 Fourth Quarter Financial Results on Monday, March 5NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/02/200711:00PR Newswire (US)Allos Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/02/200714:01PR Newswire (US)Allos Therapeutics Announces Closing of Common Stock OfferingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/01/200709:00PR Newswire (US)Allos Therapeutics Announces Pricing of Underwritten Offering of 9,000,000 Shares of Common StockNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/01/200718:19PR Newswire (US)Allos Therapeutics to Present at the 2007 JP Morgan Healthcare ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/01/200710:05PR Newswire (US)Allos Therapeutics Appoints William R. Ringo to Its Board of DirectorsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/01/200710:00PR Newswire (US)Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 Trial of Its Novel Antifolate PDX in PatienNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/12/200614:46PR Newswire (US)Results Reported at the American Society of Hematology Annual Meeting Affirm Impressive Activity of Allos Therapeutics' Novel AnNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/11/200611:00PR Newswire (US)Allos Therapeutics Added to NASDAQ Biotech IndexNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/11/200611:15PR Newswire (US)Updated Safety Analysis of Allos Therapeutics Phase 1/2 Study of PDX in Patients With Aggressive Lymphomas Demonstrates DecreaseNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
09/11/200616:56PR Newswire (US)Allos Therapeutics Announces Presentation of Updated Results From Phase 1/2 Trial of PDX in Patients With Aggressive Lymphomas aNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/11/200615:00PR Newswire (US)Updated Analysis Demonstrates Long-Term Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Receiving Sequential ChemorNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/11/200609:30PR Newswire (US)Allos Therapeutics Reports Third Quarter 2006 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/11/200618:00PR Newswire (US)Allos Therapeutics to Announce 2006 Third Quarter Financial Results on Friday, November 3NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
31/10/200614:30PR Newswire (US)Allos Therapeutics Announces Presentations on EFAPROXYN(TM) and PDX at Upcoming Scientific ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/10/200608:29PR Newswire (US)Allos Therapeutics Announces ENRICH Trial UpdateNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH

Seu Histórico Recente

BIT
S29614
Societe Generale Effekten
BIT
F15509
Vontobel Financial Produ...
COIN
FETUSD
Fetch
LSE
HAN
Hansa Investment
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados